Kylie O’Keefe: Yes absolutely. I think what I would add Kristen in addition to what Matt said, I think one of the things that we do as a commercial team which we take very seriously, is making sure we take learnings across all aspects of our business as well as making sure where there are overlaps between physician, specialties and physician target call points that we’re sharing that amongst our different teams. So if we look at Huntington’s disease specifically as Matt said obviously it’s more adult. But one of the things that is consistent is the movement to sort of subspecialty within neurology has overlapped between Upstaza and other parts of our business. And so we’re making sure it’s not an entirely overlap but there are some components of overlap. And so in that case we’re making sure that where we’re having consistent touch points that we’re sharing that across the different teams.
Kristen Kluska: Great. Thanks again.
Operator: And thank you. And our next question comes from David Lebowitz from Citi. Your line is now open.
David Lebowitz: Thank you very much for taking my question. When you think of the guidance for Duchenne in — for full year the implication is that at the high end of the guidance the revenues would actually decline by 27% in the second half. Are we to assume that guidance is just making the most conservative possible assumptions here and that things could very well work out differently as the year progresses, or should we expect a decline in the second half?
Matthew Klein: Yes. Thank you David very much for the question. Obviously I had talked a bit about how much growth we’ve been able to achieve and the reasons for that growth in the Translarna franchise. I’ll let Eric talk a little bit about the dynamics in the second half and how we’re thinking about total year guidance.
Eric Pauwels: Yes, first of all, I think we continue to see growth. So ,David I think what we’re trying to do is to really modulate a lot of these group purchase orders in countries where we have established ordering patterns that are relatively inconsistent. And so while we’re being a bit conservative in certain areas the unpredictability of the timing and the size of the orders can certainly play. But what we’ve seen fundamentally in all of these markets particularly in the Latin American markets where we continue to see orders and orders from new countries as well as the Central and the Eastern European markets and Middle Eastern markets which in the last few years have started to sort of stabilize much in terms of their ordering patterns there are still some unpredictabilities.
And because the number of patients that we have the large amount of patients in certain markets such as Brazil and Russia and a number of other key areas the timing, the size of these orders can have fluctuations between one quarter or the next. But the fundamentals are still very strong. And I think we’re very positive given the fact that we have seen quarter-on-quarter growth. So, I think as I mentioned I think we have some very nice tailwinds. I think we’re going to continue to see good growth. And we’re very confident that we’re going to be able to achieve the guidance that we’ve set out or at least that exceed it.
David Lebowitz: Got it. Thank you very much for that. And just jumping over to PKU. Given the trial the pivotal portion of the trial utilized a diet as part of the protocol. And I know the OLE that you are adding Phe into the diet. From a labeling perspective, can the OLE serve as a component to allow diet to not be a requirement for a patient, or will the labeling ultimately include on top of a diet?
